XBIO (Xenetic Biosciences) Institutional Ownership: 7.43% (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBIO Xenetic Biosciences Inc XBIO
83 GF Score
Price $3.57
GF Value $3.77
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Institutional Ownership?

Xenetic Biosciences XBIO +5.90% 83 Institutional Ownership is 7.43% as of Aug. 24, 2026. GuruFocus rates XBIO with a GF Score™ of 83/100 and a GF Value™ of $3.77 (Fairly Valued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xenetic Biosciences's institutional ownership is 7.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xenetic Biosciences's Insider Ownership is 22.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xenetic Biosciences's Float Percentage Of Total Shares Outstanding is 96.41%.

Xenetic Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences Institutional Ownership Chart

Xenetic Biosciences Historical Data

The historical data trend for Xenetic Biosciences can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 0.98 0.66 0.79 0.79 0.82 1.63 1.61 1.61 0.96 0.94
XBIO
83GF Score
Xenetic Biosciences Inc XBIO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.43% mean?
Xenetic Biosciences (XBIO) has a Institutional Ownership of 7.43% as of Aug. 24, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Institutional Ownership too high?
Xenetic Biosciences' current Institutional Ownership is 7.43%. Overall, Xenetic Biosciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Institutional Ownership compare to ADIL and PULM?
Xenetic Biosciences' Institutional Ownership of 7.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Institutional Ownership is 7.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Fairly Valued. The stock's GF Value™ is $3.77, compared to a current price of $3.57 — trading 5.3% below its estimated fair value. The current Institutional Ownership is 7.43%. Xenetic Biosciences' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Institutional Ownership is 7.43% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $3.57 is trading 5.3% below its estimated GF Value™ of $3.77. GuruFocus considers Xenetic Biosciences to be Fairly Valued.

Key valuation signals for XBIO:

  • Institutional Ownership: 7.43%
  • GF Value™: $3.77 vs. price of $3.57 (5.3% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
83GF Score

Get the complete analysis for XBIO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.57
Price
$3.77
GF Value